Abstract P1-13-06: Does histological subtype play a role in treatment decision-making for hormone receptor positive metastatic breast cancer? A study of the Southeast Netherlands breast cancer consortium

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Research

• Publication date

  2016-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1538-7445.SABCS15-P1-13-06
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients

  2023cites this paper
• Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients —A retrospective study

  2022cites this paper
• Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer

  2022cites this paper
• Long-term follow-up of early stage HER2-positive breast cancer patients treated with trastuzumab: A population-based real world multicenter cohort study

  2022cites this paper
• A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice

  2021cites this paper
• Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China

  2021influential citation
• Cost-Effectiveness of Adjuvant Immunotherapy With Cytokine-Induced Killer Cell for Hepatocellular Carcinoma Based on a Randomized Controlled Trial and Real-World Data

  2021cites this paper
• Survival in patients with HR+/HER2− metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study

  2020influential citation
• Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

  2020cites this paper
• Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study

  2019cites this paper
• Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016)

  2019cites this paper